Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.13% | 9.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.06% | 33.22% | |||
| Operating Income | 22.06% | -33.22% | |||
| Income Before Tax | 28.49% | -19.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.49% | -19.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.49% | -19.81% | |||
| EBIT | 22.06% | -33.22% | |||
| EBITDA | 22.08% | -33.26% | |||
| EPS Basic | 38.17% | -16.83% | |||
| Normalized Basic EPS | 38.20% | -16.85% | |||
| EPS Diluted | 38.17% | -16.83% | |||
| Normalized Diluted EPS | 38.20% | -16.85% | |||
| Average Basic Shares Outstanding | 15.60% | 2.51% | |||
| Average Diluted Shares Outstanding | 15.60% | 2.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||